74508-89-7

Usage

Appearance

Colorless liquid
The compound is a colorless liquid at room temperature.

Molecular weight

215.090 g/mol
The molecular weight of the compound is 215.090 grams per mole.

Uses

Pharmaceutical intermediate, agrochemical intermediate, organic synthesis intermediate
The compound is primarily used as an intermediate in the production of pharmaceuticals, agrochemicals, and other organic compounds.

Solvent

Used in various chemical processes
It is also used as a solvent in different chemical processes.

Bromomethyl group

Allows for the introduction of bromine into more complex molecules
The presence of a bromomethyl group in the chemical structure makes it a useful intermediate in organic synthesis.

Hazards and toxicity

Handle with care
It is important to handle this chemical with care due to its potential hazards and toxicity.

Upstream product

• 17201-43-3 4-cyanobenzyl bromide 
• 51359-78-5 4-(bromomethyl)benzaldehyde 
• 107-21-1 ethylene glycol 

Downstream Products

• 1093190-21-6 C₂₂H₂₀O₄ 
• 1191083-22-3 methyl 4-[4-(1,3-dioxolan-2-yl)benzyloxy]benzoate 
• 159424-54-1 (E)-2--3-phenylbicyclo<2.2.1>hepta-2,5-diene 
• 159424-56-3 (Z)-2--3-phenylbicyclo<2.2.1>hepta-2,5-diene 
• 159424-55-2 (E)-2-(p-formylstyryl)-3-phenylbicyclo<2.2.1>hepta-2,5-diene 
• 159424-57-4 (Z)-2-(p-formylstyryl)-3-phenylbicyclo<2.2.1>hepta-2,5-diene 
• 500530-86-9 (E,E)-1,4-bis[4-{(E)-4-(tert-butylthio)styryl}styryl]-2,5-didodecylbenzene 

Relevant academic research and scientific papers

Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation

In this work we describe the synthesis of potent and selective quinolone-based histone deacetylase 6 (HDAC6) inhibitors. The quinolone moiety has been exploited as an innovative bioactive cap-group for HDAC6 inhibition; its synthesis was achieved by applying a multicomponent reaction. The optimization of potency and selectivity of these products was performed by employing computational studies which led to the discovery of the diethylaminomethyl derivatives 7g and 7k as the most promising hit molecules. These compounds were investigated in cellular studies to evaluate their anticancer effect against colon (HCT-116) and histiocytic lymphoma (U9347) cancer cells, showing good to excellent potency, leading to tumor cell death by apoptosis induction. The small molecules 7a, 7g and 7k were able to strongly inhibit the cytoplasmic and slightly the nuclear HDAC enzymes, increasing the acetylation of tubulin and of the lysine 9 and 14 of histone 3, respectively. Compound 7g was also able to increase Hsp90 acetylation levels in HCT-116 cells, thus further supporting its HDAC6 inhibitory profile. Cytotoxicity and mutagenicity assays of these molecules showed a safe profile; moreover, the HPLC analysis of compound 7k revealed good solubility and stability profile.

COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND BETA2 ADRENERGIC RECEPTOR AGONIST ACTIVITY

The present invention relates to compounds acting both as muscarinic receptor antagonists and beta2 adrenergic receptor agonists, to processes for their preparation, to compositions comprising them, to therapeutic uses and combinations with other pharmace

Rotationally Restricted 1,1′-Bis(phenylethynyl)ferrocene Subunits in Macrocycles

The synthesis of macrocycles comprising a 1,1′-bis(phenylethynyl)ferrocene subunit was developed to increase the structural control over the spatial arrangement of the two cyclopentadienyl ligands of the ferrocene junction. The target structures were obtained through a modular strategy that enables the assembly of varying ring sizes from a common precursor. In particular, macrocycles were either formed by an ether formation reaction or by ring-closing metathesis reactions. The macrocycles were obtained in reasonable isolated yields, which allowed their thorough characterization by one- and two-dimensional NMR spectroscopy experiments, and the identity of one macrocycle was corroborated by single-crystal X-ray diffraction.

Towards control of dendrimer properties by reversible exchange of termini: Synthesis and characterization of diverse porphyrin dendrimers

Porphyrin dendrimers with boronic ester, aldehyde, and pyridil termini were synthesized and fully characterized. These dendrimers have the potential to change their physical and chemical properties by reversible alteration of the reactive terminal groups.

Synthesis, characterization and protein binding properties of supported dendrons

Novel benzylether type aldehyde and acetal terminated dendrons were synthesized and attached to a silica gel support; a linear spacer was also introduced as a control material. The supported dendritic compounds were mainly characterized by solid state 13C CPMAS NMR, elemental analysis and X-ray photoelectron spectroscopy (XPS) and the presence of free aldehydes was determined by the purpald test. Bovine serum albumin (BSA) protein was coupled to the dendronized support by imine bond formation, followed by irreversible reduction of the carbon-nitrogen double bond. A significant positive dendritic effect was observed on the antibody binding capacity of immobilised BSA as measured by fluorescence immunoassay (FIA). The Royal Society of Chemistry 2009.

ANTIBACTERIAL AGENTS

Antibacterial compounds of formula (I) are provided, as well as stereoisomers, pharmaceutically acceptable salts, esters, and prodrugs thereof; pharmaceutical compositions comprising such compounds; methods of treating bacterial infections by the administration of such compounds; and processes for the preparation of such compounds.

Prostanoid compounds and compositions

Prostanoid compounds are described having the formula: STR1 where A is a cyclopentane ring, which is substituted by oxo and/or hydroxy or etherified hydroxy and may be saturated or unsaturated; X is --CH=CH-- or --(CH2)2 --; R is alkyl having a terminal --COOH or ester grup; and Y is amino or substituted amino, particularly heterocyclic amino. The compounds have bronchodilator activity and/or inhibit blood platelet aggregation. The preparation and pharmaceutical formulation of the compounds is also described.